Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.
ImpediMed Limited has appointed Erik Anderson as managing director and chief executive officer, effective 7 April 2026, as it seeks to accelerate commercial execution, particularly in the United States. Outgoing CEO Dr Parmjot Bains will remain with the company until 30 June 2026 in an advisory role to ensure an orderly leadership transition.
The board said the change comes as ImpediMed’s breast cancer-related lymphoedema offering gains momentum and the business moves toward cash flow break-even. Under Dr Bains, the company expanded its addressable market with new SOZO indications and broader U.S. reimbursement, and the board believes Anderson’s U.S. medtech experience will help drive sales growth, deepen health system engagement, and support long-term value creation.
Investors will have an opportunity to hear from the new CEO and the leadership team in a webinar scheduled for 7 April 2026. The session is intended to outline strategic priorities under Anderson’s tenure and provide additional context on ImpediMed’s next phase of growth in key markets.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company focused on bioimpedance spectroscopy solutions, led by its SOZO platform. The company’s products target breast cancer-related lymphoedema, body composition monitoring for weight management, and fluid status monitoring in heart health, with a growing commercial focus on the United States healthcare market.
YTD Price Performance: -55.88%
Average Trading Volume: 6,423,531
Technical Sentiment Signal: Sell
Current Market Cap: A$31.6M
See more insights into IPD stock on TipRanks’ Stock Analysis page.